This trial is testing whether the drug eculizumab can help treat HELLP syndrome, a disease affecting pregnant women. The drug blocks part of the immune system. Researchers will see if the drug is effective and benefits both the mother and fetus.
3 Primary · 3 Secondary · Reporting Duration: Baseline, 72 hours
15 Total Participants · 1 Treatment Group
Primary Treatment: Eculizumab · No Placebo Group · Phase 1
Age 18 - 50 · Female Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: